Research and Markets has announced the addition of the "Sickle Cell Anemia Pipeline Highlights - 2017" drug pipelines to their offering.

Sickle Cell Anemia Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Sickle Cell Anemia market. It covers emerging therapies for Sickle Cell Anemia in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Sickle Cell Anemia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Sickle Cell Anemia pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Sickle Cell Anemia pipeline products by the company.

Short-term Launch Highlights:

Find out which Sickle Cell Anemia pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Sickle Cell Anemia Pipeline by Stages

2. Sickle Cell Anemia Pipeline by Drug Class

3. Sickle Cell Anemia Pipeline by Company

4. Sickle Cell Anemia Phase 3 Clinical Trial Insights

5. Sickle Cell Anemia Phase 2 Clinical Trial Insights

6. Sickle Cell Anemia Phase 1 Clinical Trial Insights

7. Sickle Cell Anemia Preclinical Research Insights

8. Sickle Cell Anemia Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/8qxmcj/sickle_cell